Drug Profile
Research programme: cancer therapies - Avidimer
Alternative Names: ATI-001Latest Information Update: 14 Jun 2011
Price :
$50
*
At a glance
- Originator Avidimer Therapeutics; Dow Chemical; University of Michigan
- Developer Avidimer Therapeutics
- Class Gene therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 22 Jan 2008 Preclinical development is ongoing
- 16 Aug 2005 Preclinical trials in Cancer in USA (unspecified route)